Morningstar

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...
Morningstar

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice ...
The Business Journals

CSL reveals King of Prussia job losses at Vifor subsidiary amid 15% global workforce reduction

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...
Law

Vifor (international) AG v. Orbicular Pharmaceutical Technologies Private Limited

Orbicular Pharmaceutical Technologies was hit with a patent infringement lawsuit on Oct. 20 in New Jersey District Court over its planned generic version of the iron deficiency drug Injectafer. The ...
Longview News-Journal

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and ...